

Soonmyung Paik

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2245284/soonmyung-paik-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

92
papers

29,543
citations

45
h-index

96
g-index

96
ext. papers

33,932
ext. citations

11.6
avg, IF

6.36
L-index

#	Paper	IF	Citations
92	A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. <i>New England Journal of Medicine</i> , 2004 , 351, 2817-26	59.2	4778
91	Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. <i>New England Journal of Medicine</i> , 2005 , 353, 1673-84	59.2	4284
90	Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3997-4013	2.2	2593
89	Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. <i>Lancet, The</i> , 2014 , 384, 164-72	40	2177
88	American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2784-95	2.2	2145
87	Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. <i>Journal of Clinical Oncology</i> , 2006 , 24, 3726-34	2.2	2031
86	Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. <i>Journal of Clinical Oncology</i> , 2008 , 26, 778-85	2.2	1254
85	Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. <i>New England Journal of Medicine</i> , 2018 , 379, 111-121	59.2	959
84	Nanomaterials for theranostics: recent advances and future challenges. <i>Chemical Reviews</i> , 2015 , 115, 327-94	68.1	883
83	Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. <i>New England Journal of Medicine</i> , 2015 , 373, 2005-14	59.2	865
82	Use of archived specimens in evaluation of prognostic and predictive biomarkers. <i>Journal of the National Cancer Institute</i> , 2009 , 101, 1446-52	9.7	752
81	Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. <i>Journal of Clinical Oncology</i> , 2006 , 24, 2019-27	2.2	746
80	erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. <i>Journal of the National Cancer Institute</i> , 1998 , 90, 1361-70	9.7	549
79	Development of the 21-gene assay and its application in clinical practice and clinical trials. <i>Journal of Clinical Oncology</i> , 2008 , 26, 721-8	2.2	440
78	Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1677-83	2.2	433
77	Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience. <i>Journal of the National Cancer Institute</i> , 2002 , 94, 852-4	9.7	399
76	HER2 status and benefit from adjuvant trastuzumab in breast cancer. <i>New England Journal of Medicine</i> , 2008 , 358, 1409-11	59.2	363

75	Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. <i>Advances in</i>	5.1	293
74	CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer. <i>New England Journal of Medicine</i> , 2016 , 374, 211-22	59.2	283
73	Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value. <i>Clinical Cancer Research</i> , 2012 , 18, 6531-41	12.9	225
72	HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. <i>Journal of the National Cancer Institute</i> , 2000 , 92, 1991-8	9.7	222
71	Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. <i>New England Journal of Medicine</i> , 2019 , 380, 2395-2405	59.2	208
70	Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen. <i>Oncologist</i> , 2007 , 12, 631-5	5.7	152
69	Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. <i>Lancet, The</i> , 2019 , 394, 2155-2164	4.0	152
68	Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20. <i>Breast Cancer Research and Treatment</i> , 2011 , 127, 133-42	4.4	149
67	Gene-expression-based prognostic assays for breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2010 , 7, 340-7	19.4	132
66	Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4512-9	2.2	128
65	Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. <i>Annals of Oncology</i> , 2015 , 26, 1280-91	10.3	127
64	Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. <i>Lancet Oncology, The</i> , 2015 , 16, 1037-1048	21.7	115
63	Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes: Secondary Analysis of NSABP C-07/NRG Oncology Randomized Clinical Trial. <i>JAMA Oncology</i> , 2016 , 2, 1162-9	13.4	106
62	A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes. <i>BMC Cancer</i> , 2010 , 10, 101	4.8	102
61	Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4160-7	2.2	90
60	Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1340-7	2.2	88
59	21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	84
58	Technology insight: Application of molecular techniques to formalin-fixed paraffin-embedded tissues from breast cancer. <i>Nature Clinical Practice Oncology</i> , 2005 , 2, 246-54		77

57	NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2. <i>Journal of Clinical Oncology</i> , 2020 , 38, 444-453	2.2	76
56	Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31. <i>Journal of the National Cancer Institute</i> , 2013 , 105, 1782-8	9.7	72
55	Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial. <i>JAMA Oncology</i> , 2020 , 6, 367-374	13.4	59
54	Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , 2019 , 20, 88-99	21.7	58
53	Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2-Positive Breast Cancer: Analysis of the NSABP B-31 Trial. <i>JAMA Oncology</i> , 2017 , 3, 335-341	13.4	56
52	Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor-Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-28 and B-41. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2252-60	2.2	56
51	Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention. <i>Cancer Discovery</i> , 2013 , 3, 812-25	24.4	48
50	21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer. <i>Npj Breast Cancer</i> , 2018 , 4, 37	7.8	47
49	Selective Cytotoxicity of the NAMPT Inhibitor FK866 Toward Gastric Cancer Cells With Markers of the Epithelial-Mesenchymal Transition, Due to Loss of NAPRT. <i>Gastroenterology</i> , 2018 , 155, 799-814.e13	13.3	46
48	Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08. <i>Journal of the National Cancer Institute</i> , 2013 , 105, 989-92	9.7	46
47	Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. <i>Clinical Cancer Research</i> , 2015 , 21, 544-52	12.9	45
46	Is gene array testing to be considered routine now?. <i>Breast</i> , 2011 , 20 Suppl 3, S87-91	3.6	45
45	Prognostic impact of deficient mismatch repair (dMMR) in 7,803 stage II/III colon cancer (CC) patients (pts): A pooled individual pt data analysis of 17 adjuvant trials in the ACCENT database.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3507-3507	2.2	36
44	Targeting mutant with CRISPR-Cas9 controls tumor growth. <i>Genome Research</i> , 2018 ,	9.7	33
43	Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative. <i>Oncotarget</i> , 2016 , 7, 24172-8	3.3	32
42	Incidence of Late Relapses in Patients With HER2-Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3425-3435	2.2	27
41	Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2019 , 111, 867-871	9.7	24
40	Expression analysis of mRNA in formalin-fixed, paraffin-embedded archival tissues by mRNA in situ hybridization. <i>Methods</i> , 2006 , 38, 253-62	4.6	24

39	NSABP B-51/RTOG 1304: Randomized phase III clinical trial evaluating the role of postmastectomy chest wall and regional nodal XRT (CWRNRT) and post-lumpectomy RNRT in patients (pts) with documented positive axillary (Ax) nodes before neoadjuvant chemotherapy (NC) who convert to pathologically negative Ax nodes after NC.. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS1141-TPS1141	2.2	23
38	Prognosis of stage III colorectal carcinomas with FOLFOX adjuvant chemotherapy can be predicted by molecular subtype. <i>Oncotarget</i> , 2017 , 8, 39367-39381	3.3	23
37	A polygenic risk score for breast cancer in women receiving tamoxifen or raloxifene on NSABP P-1 and P-2. <i>Breast Cancer Research and Treatment</i> , 2015 , 149, 517-23	4.4	19
36	21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology. <i>Breast Cancer Research and Treatment</i> , 2018 , 168, 69-77	4.4	18
35	Peripheral natural killer cells and myeloid-derived suppressor cells correlate with anti-PD-1 responses in non-small cell lung cancer. <i>Scientific Reports</i> , 2020 , 10, 9050	4.9	16
34	Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation. <i>Lung Cancer</i> , 2018 , 124, 168-178	5.9	15
33	Gene expression-based prognostic and predictive markers for breast cancer: a primer for practicing pathologists. <i>Archives of Pathology and Laboratory Medicine</i> , 2009 , 133, 855-9	5	15
32	NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2 breast cancer. <i>Breast Cancer Research</i> , 2019 , 21, 133	8.3	15
31	Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in RET-Rearranged Lung Adenocarcinoma. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 2238-48	6.1	14
30	Clinical trial methods to discover and validate predictive markers for treatment response in cancer. <i>Biotechnology Annual Review</i> , 2003 , 9, 259-67		14
29	Tumour sidedness and intrinsic subtypes in patients with stage II/III colon cancer: analysis of NSABP C-07 (NRG Oncology). <i>British Journal of Cancer</i> , 2018 , 118, 629-633	8.7	13
28	PI3K/AKT/ β Catenin Signaling Regulates Vestigial-Like 1 Which Predicts Poor Prognosis and Enhances Malignant Phenotype in Gastric Cancer. <i>Cancers</i> , 2019 , 11,	6.6	11
27	Destabilization of β catenin and RAS by targeting the Wnt/ β catenin pathway as a potential treatment for triple-negative breast cancer. <i>Experimental and Molecular Medicine</i> , 2020 , 52, 832-842	12.8	10
26	Cancer Cell Line Panels Empower Genomics-Based Discovery of Precision Cancer Medicine. <i>Yonsei Medical Journal</i> , 2015 , 56, 1186-98	3	10
25	Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma. <i>Oncotarget</i> , 2015 , 6, 44971-84	3.3	10
24	Bcl-2-dependent synthetic lethal interaction of the IDF-11774 with the V0 subunit C of vacuolar ATPase (ATP6V0C) in colorectal cancer. <i>British Journal of Cancer</i> , 2018 , 119, 1347-1357	8.7	10
23	Dynamic changes in circulating PD-1CD8 T lymphocytes for predicting treatment response to PD-1 blockade in patients with non-small-cell lung cancer. <i>European Journal of Cancer</i> , 2021 , 143, 113-126	7.5	9
22	Mouse-human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck. <i>British Journal of Cancer</i> , 2020 , 123, 1720-1729	8.7	8

21	A Therapeutic Strategy for Chemotherapy-Resistant Gastric Cancer via Destabilization of Both E-Catenin and RAS. <i>Cancers</i> , 2019 , 11,	6.6	7
20	The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40. <i>Annals of Surgical Oncology</i> , 2017 , 24, 1853-1860	3.1	7
19	Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer. <i>Oncotarget</i> , 2017 , 8, 38389-38398	3.3	7
18	Establishment and characterization of patient-derived xenografts as preclinical models for head and neck cancer. <i>BMC Cancer</i> , 2020 , 20, 316	4.8	7
17	Association of colon cancer (CC) molecular signatures with prognosis and oxaliplatin prediction-benefit in the MOSAIC Trial (Multicenter International Study of Oxaliplatin/5FU-LV in the Adjuvant Treatment of Colon Cancer).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3503-3503	2.2	6
16	Molecular subtypes of colorectal cancer in pre-clinical models show differential response to targeted therapies: Treatment implications beyond KRAS mutations. <i>PLoS ONE</i> , 2018 , 13, e0200836	3.7	5
15	Systematic evaluation of scoring methods for Ki67 as a surrogate for 21-gene recurrence score. <i>Npj Breast Cancer</i> , 2021 , 7, 13	7.8	5
14	Immune Signature to Predict Trastuzumab Benefit: Potential and Pitfalls. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3671-2	2.2	4
13	EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E-Mutant NSCLC Cell Lines. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 1627-36	6.1	4
12	Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017 , 163, 255-262	4.4	3
11	Genomic profiling of the residual disease of advanced high-grade serous ovarian cancer after neoadjuvant chemotherapy. <i>International Journal of Cancer</i> , 2020 , 146, 1851-1861	7.5	3
10	Earlier-Phased Cancer Immunity Cycle Strongly Influences Cancer Immunity in Operable Never-Smoker Lung Adenocarcinoma. <i>iScience</i> , 2020 , 23, 101386	6.1	3
9	An Improved, Assay Platform Agnostic, Absolute Single Sample Breast Cancer Subtype Classifier. <i>Cancers</i> , 2020 , 12,	6.6	3
8	AIRVF: a filtering toolbox for precise variant calling in Ion Torrent sequencing. <i>Bioinformatics</i> , 2018 , 34, 1232-1234	7.2	2
7	BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 Therapy. <i>Cancer Research and Treatment</i> , 2019 , 51, 1527-1539	5.2	2
6	Association between <i>Fusobacterium nucleatum</i> and patient prognosis in metastatic colon cancer. <i>Scientific Reports</i> , 2021 , 11, 20263	4.9	2
5	Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab. <i>Pharmacogenetics and Genomics</i> , 2018 , 28, 147-152	1.9	2
4	Validation of the NSABP/NRG Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831. <i>JNCI Cancer Spectrum</i> , 2020 , 4, pkaa058	4.6	1

- 3 Genomic landscape of extraordinary responses in metastatic breast cancer. *Communications Biology*, **2021**, 4, 449 6.7 1
- 2 Tissue Microarrays **2006**, 31-44
- 1 Assays for Gene Amplification **2006**, 65-77